[ad_1]
Management says the fundamental technology underpinning the trials is the proprietary nanobody from its “NanoMabs” platform, which targets what is known as programmed death-ligand 1 (PD-L1)-positive expression in NSCLC.
PD-L1 is a regulatory molecule expressed in T cells, which has an immunoregulatory function by dampening the immune response when bound to one of its complementary ligands.
If high amounts of PD-L1 are found on or in cancer cells, immunotherapy medicines known as “immune checkpoint inhibitors” may be used. Those medicines prevent the PD-L1 protein from putting the brakes on T cells and frees them to fight cancer.
In August last year, Radiopharm confirmed it had entered a collaboration agreement with US-based Lantheus for the development of “NM-01″ – a nanobody made using genetically-engineered, single-domain antibodies capable of being tagged or labelled with radioisotopes to potentially diagnose and treat multiple tumour types.
In a separate agreement, Radiopharm acquired from NanoMab the imaging rights of NM-01 for the strategic Chinese market and worldwide IP rights for any therapeutic use.
Under the collaboration agreement, Lantheus will provide the diagnostic product candidate of NM-01 to Radiopharm for use in its therapeutic clinical trials, and NM-01 will be used to assess PD-L1 expression during patient selection.
Both Radiopharm and Lantheus have the option to expand their collaboration to additional assets and potential licensing opportunities in the former’s pipeline.
About 300,000 new lung cancer cases are expected to be diagnosed in the US alone by the end of 2023, 81 per cent of which are estimated to be NSCLC patients. It is estimated that there were more than 2.2 million cases of lung cancer in 2020.
Is your ASX-listed company doing something interesting? Contact: mattbirney@bullsnbears.com.au
[ad_2]
Source link
